What is Axbio?
Founded in 2016 and headquartered in Silicon Valley, Axbio is a pioneering startup deeply entrenched in the precision medicine and healthcare industries. The company focuses on the research and development of core technologies, manufacturing next-generation gene sequencing and precision diagnostic equipment, and delivering comprehensive solutions to the sector. With R&D centers in Silicon Valley and Shenzhen Tsinghua University Research Institute, Axbio leverages a robust team comprising serial Silicon Valley entrepreneurs, global corporate executives, and seasoned scientists. Their collective expertise spans integrated circuits, semiconductor technology, biochemistry, organic chemistry, surface physics, microfluidics, physical chemistry, big data, and artificial intelligence, providing a full spectrum of capabilities for molecular diagnostics and gene sequencing product development.
How much funding has Axbio raised?
Axbio has raised a total of $100.3M across 2 funding rounds:
Debt
$350K
Series B
$100M
Debt (2020): $350K with participation from PPP
Series B (2022): $100M led by Alibaba Group and Yunfeng Capital
Key Investors in Axbio
Alibaba Group
Headquartered in Hong Kong, China, Alibaba Group is an e-commerce, retail, Internet, and technology conglomerate holding company. The company's businesses are comprised of core commerce, cloud computing, digital media and entertainment, and innovation initiatives.
Yunfeng Capital
Yunfeng Capital aims to provide not only capital but also share experience and lessons learned with portfolio companies, assisting them in strategy formulation, organizational optimization, and brand recognition. They focus on nurturing young entrepreneurs with the potential to become industry leaders and manage various US Dollar, RMB, and Special Funds, with a focus on internet, technology, healthcare, media & entertainment, financial services, logistics, and consumer sectors.
What's next for Axbio?
The substantial enterprise-level funding, particularly the recent major strategic investment, positions Axbio for accelerated growth and market expansion. This capital infusion is expected to fuel further innovation in gene sequencing and precision diagnostics, enabling the company to scale its operations and solidify its market presence. The company's strategic focus on precision medicine, coupled with its strong technological foundation and experienced leadership, suggests a trajectory towards becoming a dominant player in the healthcare technology landscape. Future developments will likely involve expanding its solution offerings and potentially forging new strategic partnerships to enhance its reach and impact.
See full Axbio company page
